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Abstract—Several neurotrophic factors (NTF) are shown to be neuroprotective and neurorestorative in pre-clinical
animal models for Parkinson’s disease (PD), particularly in models where striatal dopamine neuron innervation
partially exists. The results of clinical trials on late-stage patients have been modest. Subthalamic deep brain
stimulation (STN DBS) is a proven treatment for a selected group of advanced PD patients. The cerebral dopamine
neurotrophic factor (CDNF) is a promising therapeutic protein, but its eﬀects in animal models of late-stage PD
have remained under-researched. The interactions of NTF and STN DBS treatments have not been studied before.
We found that a nigral CDNF protein alone had only a marginal eﬀect on the behavioral deﬁcits in a late-stage
hemiparkinsonian rat model (6-OHDA MFB). However, CDNF improved the eﬀect of acute STN DBS on front limb
use asymmetry at 2 and 3 weeks after CDNF injection. STN lesion—modeling chronic stimulation—had an additive
eﬀect in reducing front limb use in the cylinder test and apomorphine-induced rotation. The combination of CDNF
and acute STN DBS had a favorable eﬀect on striatal tyrosine hydroxylase. This study presents a novel additive
beneﬁcial eﬀect of NTF and STN DBS, which might be explained by the interaction of DBS-induced endogenous
NTFs and exogenously injected CDNF. SNpc can be reached via similar trajectories used in clinical STN DBS, and
this interaction is an important area for future studies.  2018 The Authors. Published by Elsevier Ltd on behalf of IBRO.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Parkinson’s disease (PD) is a progressive
neurodegenerative disease. The cardinal symptoms of
PD—tremor, rigidity, postural instability, and
bradykinesia—are mainly caused by shortage of
dopamine due to dopamine neuron death in the
substantia nigra pars compacta (SNpc). The best
available drugs—levodopa in combination with DDC and
COMT inhibitors and dopamine agonists—act by
replacing lost dopamine in the brain, leading tohttps://doi.org/10.1016/j.neuroscience.2018.01.052
0306-4522/ 2018 The Authors. Published by Elsevier Ltd on behalf of IBRO.
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250alleviation of the motor symptoms. However, in the late
stages of the disease, these drugs lose their
eﬀectiveness or begin to cause debilitating side eﬀects.
Deep brain stimulation (DBS) of the subthalamic
nucleus (STN) provides an eﬃcient symptomatic control
for some patients whose PD has progressed to a late
stage (Krack et al., 2003; Castrioto et al., 2011).
Experimental DBS is often termed high-frequency
stimulation (HFS), alluding to the ﬁnding that only
frequencies higher than about 60 Hz alleviate the motor
symptoms produced in the animal models of PD
(Fogelson et al., 2005), and the standard 130-Hz fre-
quency used produces mainly the inhibition of STN cells
(Tai et al., 2003). In most animal studies, stimulation
comes from an external pulse generator that limits the
duration of continuous HFS to hours, or at the most, days.
Long-term STN HFS and DBS can be mimicked by the
lesioning of the STN (STNL), and originally DBS was real-
ized to reproduce the eﬀects of therapeutic stereotactic
lesions (Benazzouz et al., 1993). The eﬃcacy of STNL
was originally veriﬁed by chemical ibotenic acid (IBOT)
lesions in a primate MPTP model of PD (Bergmanons.org/licenses/by-nc-nd/4.0/).
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patients with PD (Jourdain et al., 2014). Additionally,
STN DBS has both local excitatory eﬀects aside from inhi-
bition (McIntyre et al., 2004) and complex network level
eﬀects (McIntyre and Hahn, 2010) such as eﬀects on beta
coupled high-frequency activity in motor cortex (Yang
et al., 2014). According to animal studies, DBS is able
to cause increased striatal dopamine transmission
(Meissner et al., 2001; Walker et al., 2009; Pazo et al.,
2010) and aﬀect the downstream motor nuclei (Shehab
et al., 2014). There is some experimental evidence that
DBS may have a neuroprotective eﬀect (Temel et al.,
2006; Harnack et al., 2008; Spieles-Engemann et al.,
2010; Musacchio et al., 2017), but clinical evidence for
neuroprotection is lacking (Harnack and Kupsch, 2010).
There has been an extensive search for drugs that
can stop the progression of dopamine neuron
degeneration and restore dopaminergic phenotype and
function in dying neurons (Airavaara et al., 2012b;
Bartus and Johnson, 2017a,b). Neurotrophic factors
(NTFs) are able to protect and even restore dopamine
neuron degeneration. NTFs are a group of proteins with
variable biological actions (Airaksinen and Saarma,
2002; Lindholm et al., 2016). Importantly, both glial cell
line-derived neurotrophic factor (GDNF) and neurturin
(NRTN) have been shown to be neurorestorative in rodent
and primate models of PD in vivo (Airavaara et al.,
2012b). The eﬃcacy has been found in partial lesion mod-
els where tyrosine hydroxylase (TH) immunoreactive
ﬁbers in the striatum still exist. Recently, it was reported
that the retrograde transport of cerebral dopamine neu-
rotrophic factor (CDNF) from the striatum to substantia
nigra (Voutilainen et al., 2011) depends on striatal dopa-
mine innervation (Ma¨tlik et al., 2017). Additionally, BDNF
(Spina et al., 1992), FGF-2 (Otto and Unsicker, 1990) and
VEGF (Yasuhara et al., 2004) have been eﬀective preclin-
ical trials. Two NTFs—GDNF and neurturin—have been
in clinical trials, where they have been administered
directly into the striatum either GDNF as a recombinant
protein or NRTN in an adeno-associated virus (AAV) gene
therapy, but their eﬃcacy has been variable (Kordower
et al., 1999; Gill et al., 2003; Lang and Obeso, 2004;
Lang et al., 2006; Penn et al., 2006; Patel and Gill,
2007; Bartus and Johnson, 2017b). Clinical studies have
usually been carried out on late-stage patients, but a
recent NRTN study showed positive eﬀects in a sub-
group of patients with less-progressed disease (Olanow
et al., 2015). Analysis of the brains of PD patients has
shown that there is minimal or no putaminal TH
immunoreactive innervation after 5 years post-diagnosis
(Kordower et al., 2013). Therefore, the relatively rapid
development of putaminal dopaminergic axonopathy
should be taken into account in future trials (Tenenbaum
and Humbert-Claude, 2017), particularly when there are
radiolabeled ligands with which to study the functionality
of dopamine terminals. Similarly, several NTFs have been
eﬀective in partial lesion models of PD; but with complete
lesions, they have not restored dopamine neurites in the
striatum (Airavaara et al., 2012b; Domanskyi et al., 2015).
The CDNF/MANF protein family has a neurorestorative
potential similar to GDNF and NRTN (Lindholm et al.,2007; Voutilainen et al., 2009; Lindahl et al., 2017). In a
rat 6-OHDAmodel of PD where 6-OHDA was administered
to the striatum, both CDNF and mesencephalic astrocyte-
derived neurotrophic factor (MANF) have been shown to
be neuroprotective and neurorestorative (Lindholm et al.,
2007; Voutilainen et al., 2009, 2011; Ren et al., 2013;
Ba¨ck et al., 2013a). This was also the case for CDNF in
a mouse MPTP model of PD (Airavaara et al., 2012a).
However, the eﬀects of CDNF have not been studied in
medial forebrain (MFB) 6-OHDA models of PD where
dopamine depletion is nearly complete. In the clinic, STN
DBS is used mostly for late-stage PD, where the caudate
putamen is devoid of TH+ ﬁbers and dopamine depletion
is already severe. Therefore, the likelihood of any neu-
rorestorative therapy alone increasing endogenous
dopaminergic activity is limited.
The aim of the current experiments was to study
whether CDNF has a neurorestorative eﬀect in a late-
stage parkinsonian model (MFB lesion) and whether
CDNF and DBS are synergistically neurorestorative in
this model. A MFB 6-OHDA lesion was used instead of
a striatal lesion, and CDNF in combination with or
without STN DBS was employed. STNL was used to
model long-term DBS.EXPERIMENTAL PROCEDURES
Animals
A total of 242 male Wistar rats weighing 220–300 g at the
time of ﬁrst operation were used. Rats were housed
under a light–dark cycle at an ambient temperature of
20–23 C. Food pellets (Harlan Teklad Global diet,
Holland) and tap water were available ad libitum. The
experimental design was approved by the Committee for
Animal Experiments of the University of Helsinki and the
chief veterinarian of the County Administrative Board for
2008–2010 and by the National Animal Experiment Board
for 2011–2015. Animal experiments were conducted
according to EU regulations (EU Directive 2010/63/EU)
and Finnish legislation (Finnish Act on the Protection of
Animals Used for Scientiﬁc or Educational Purposes
[497/2013] and the Government Decree on the Protection
of Animals Used for Scientiﬁc or Educational Purposes).
The laboratory experiment protocol approval numbers
were ESAVI/5459/04.10.03/2011 and ESAVI/6959/04.
10.03/2012.Surgical procedures
The stereotaxic operations were performed under
isoﬂurane anesthesia, as described in previous studies
(Lindholm et al., 2007); (Voutilainen et al., 2009). 6-
Hydroxypamine (6-OHDA, 10 lg) was injected into either
the left anterior (A/P 2.0, L/M +2.0, D/V 8.3; adapted
from (Shi et al., 2004) for the STN HFS and STN lesioning
experiments (Experiments 3 and 4) or left posterior med-
ial forebrain bundle (A/P 4.4, L/M +1.2, D/V 8.3) as
described in (Hudson et al., 1993, 1994) for the NTF only
experiments (Experiments 1 and 2). NTFs (GDNF,
Amgen, Thousand Oaks, CA, USA; human recombinant
CDNF (produced in CHO cells by Biovian, Turku, Fin-
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above the left SNpc (NTFs in 10 ml PBS, 0.5 ml/min, nee-
dle left in place for additional 4 min; A/P 5.4, M/L 2.0, D/
V 8.3 from skull) ipsilateral to the lesion. MS308 elec-
trodes (Plastics1, San Diego, CA, USA) were implanted
in the ipsilateral STN (A/P 3.6; M/L 2.3; D/V 8.0). All
coordinates relative to the bregma were according to the
stereotactic rat brain atlas (Paxinos and Watson, 1998).
The electrodes were ﬁxed to skull via dental cement and
screws. After the electrode implantation, rats were
housed in individual cages. Lidocaine was used as a local
anesthetic during surgery. Animals received 0.025 mg/kg
buprenorphine s.c. (Temgesic; Indivior, Slough, UK) for
post-operative pain relief. The left STN was lesioned via a
slow infusion of IBOT (A/P 3.6; M/L 2.3; D/V 8.0; 10 mg
in 1 ml PBS; #329130010, Acros Organics, Belgium).
Excessive rotational behavior after STN lesioning was
treated with i.p. 4% chloral hydrate 100 mg/kg (Sigma–
Aldrich #C8383, St. Louis, MO, USA).Study designsExperiment 1, CDNF dose response given at 4 weeks
after MFB 6-OHDA. The rats (n=90) received a 6-OHDA
(10 mg) injection into the left MFB. Four weeks later, the
rats received CDNF 1 mg, 3.3 mg, 10 mg, 33 mg, or 100 mg
(n=12–18), GDNF 100 mg (n=5) or PBS (n=18) left
intranigral injections. The degree of lesion and the eﬀects
of NTFs were evaluated with repeated apomorphine-
induced rotation tests andTH immunoreactivity at 16
weeks after NTF administration (Fig. 1A).
Experiment 2, CDNF 10 mg given at 1 week after MFB
6-OHDA. The rats (n= 43) received a 6-OHDA (10 mg)
injection into the left MFB, and 1 week later, they
received 10 mg of CDNF (n= 13) or GDNF (n= 15), or
PBS only (n= 15) above the left SNpc. Apomorphine-
induced rotation tests were at weeks 2, 4, 6, and 8 after
NTF injection (Fig. 2A). Biochemical analysis was done
with TH immunohistochemistry (IHC) for the evaluation
of TH+ ﬁbers in the striatum and TH+ cell counts in
the SNpc.
Experiment 3, the combination of CDNF and STN HFS
in MFB 6-OHDA PD model. The rats (n= 46) received a
unilateral MFB 6-OHDA injection as described above and
adequate lesioning was veriﬁed with an amphetamine-
induced (2.5 mg/kg, i.p., Sigma–Aldrich, Saint Louis,
MO, USA) rotation test at 6 days after 6-OHDA
injection. Seven days after the 6-OHDA, 26 rats
received CDNF 10 mg (n= 15) or PBS injection (n=
11) above the left SNpc, and stimulation electrodes
were implanted with the tips aimed at the STN. An
additional nine rats were selected for the control arm
without electrode. Six rats died or had to be euthanized
prematurely during the experiment, leaving 22 rats
surviving at the end of the experiment in the electrode
arm and seven control rats without electrode. The eﬀect
of STN DBS was measured by stimulation-induceddyskinesia and by repeated cylinder tests with no
stimulation (baseline) and at two stimulation amplitudes.
The stimulation amplitude for cylinder tests was chosen
individually for each rat based on the stimulation-
induced dyskinesias; amplitude 1 was chosen to be just
below any dyskinesias, and amplitude 2 was chosen as
the amplitude below sustained front paw dyskinesias.
The stimulation amplitudes chosen the ﬁrst week after
implantation were kept constant throughout the study.
Biochemical analysis was done measuring striatal
concentrations of dopamine (DA) and DA metabolites
with high-performance liquid chromatography (HPLC) (at
4 weeks) or with TH and dopamine transporter (DAT)
IHC (at 7 weeks) (Fig. 3A).
Experiment 4, the combination of CDNF and STN
lesion in MFB 6-OHDA PD model. The rats (n= 63)
received a unilateral MFB 6-OHDA injection as above,
and after 6 days, the rats underwent amphetamine-
induced rotation test to conﬁrm adequate lesioning.
After the test, 59 rats were selected to continue
receiving CDNF 10 mg or PBS injection above the left
SNpc and IBOT injection or PBS injection to the STN
seven days after 6-OHDA injection. After CDNF and
IBOT lesioning, a total of four rats were found dead in
their cages or had to be euthanized prematurely, 54 rats
surviving at the end of experiment (4 or 7 weeks). There
were four groups in this experiment. Group one received
PBS + PBS (n= 12), group two received CDNF +
PBS (n= 11), group three received PBS + IBOT (n=
14), and group four received CDNF + IBOT (n= 17).
The behavioral eﬀect was measured with repeated
cylinder tests and apomorphine-induced rotation tests.
The biochemical eﬀect was measured by HPLC (4
weeks) or IHC (7 weeks; Fig. 4A).Behavioral assaysApomorphine-induced rotations. Following a 30-min
habituation period, a single injection of 0.1 mg/kg of
apomorphine (Sigma Aldrich, Saint Louis, MO, USA)
was administered subcutaneously, and the rotational
behavior was recorded for 60 min. The results are
presented as net contralateral rotations, where the
ipsilateral rotations are subtracted from the contralateral
rotations.
STN HFS-induced dyskinesias. On a 0–4 scale, the
dyskinesia elicited by STN HFS was assessed on four
diﬀerent dyskinesia subgroups: orofacial, axial, front
limb, and locomotive dyskinesia. The scale used was
adapted from previous studies (Pavon et al., 2006) and
modiﬁed: 0 = no dyskinesia, 1 = transient (<2s) or
unclear, 2 = infrequent and mild or decays strongly
(<10 s), 3 = marked, long-lasting (>10 s), frequent
(>50%), and 4 = extreme, minimal decay (>60 s),
almost all the time. The highest score with a single or
more fulﬁlled criteria was chosen for each data point. All
the stimulation currents were scored for each dyskinesia
Fig. 1. Eﬀects of various doses of intranigral CDNF injection in a 6-OHDA MFB lesion. (A) Study design of experiment 1; NTFs were administered 4
weeks after 6-OHDA. (B) Evolution of apomorphine-induced rotations over time. (C) All apomorphine-induced rotations post-NTF injection
compared to rotations at 4 weeks. (D) Average body weight 1 week after growth factor injection compared to body weight before growth factor
injection. (E) Tyrosine-hydroxylase-stained striatal optical density of TH+ ﬁbers compared to contralateral side. (F) Substantia nigra TH+ cell
numbers compared to the contralateral side. Data expressed as mean ± SEM, **p< 0.01, ***p< 0.0001.
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current stepwise (0, 25, 50, 75, 100, 125, 150, 200,
250, 300, 350, and 400 mA) or until the development of
severe dyskinesias, with each step lasting for at least
10 s (as described in our unpublished study, which Huo-
tarinen et al. submitted). The overall amount of
stimulation-induced dyskinesias was estimated by a dysk-
inesia score representing the sum of all dyskinesia sub-
types over all amplitudes.Cylinder tests. Rats were tested in a 25-cm diameter
cylinder for the front limb contacts during the vertical
rearing movement. Rats were recorded for a maximum
of 10 min or until the rat reared 20 times. The counting
of contacts was done from a video by a blinded
observer. After the baseline cylinder test without
stimulation, the rats were tested for stimulation-induced
dyskinesias to determine individual stimulation
amplitudes.
Fig. 2. (A) Study design of experiment 2 for testing intranigral CDNF 10 mg given 1 week after 6-OHDA. (B) Apomorphine-induced contralateral
rotations. (C) Tyrosine-hydroxylase-stained striatal optical density of TH+ ﬁbers compared to contralateral side. (D) TH+ cell count compared to
contralateral non-lesioned site. Data expressed as mean ± SEM.
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The animals were anesthetized with an overdose of
pentobarbital (90 mg/kg, i.p., Mebunat, Orion Oyj,
Espoo, Finland) and perfused transcardially PBS
followed by 4% paraformaldehyde. The removed brains
were post-ﬁxed in paraformaldehyde overnight and
stored in 20% sucrose at 4 C. Frozen brains were cut
into 40-lm-thick coronal sections in a series of six with
a gliding microtome (Leica Biosystems, Newcastle, UK).
In experiments 1 and 2, the free-ﬂoating sections were
stained with mouse anti-TH antibody (1:2000, MAB318,
Millipore, Billerica, MA, USA), as previously described
(Voutilainen et al., 2009).
In experiment 3, the endogenous peroxidase activity
of the free-ﬂoating sections was quenched for 30 min in
0.3% hydrogen peroxide solution. For the anti-DAT
staining, the sections were incubated in 10 mM citrate
buﬀer, pH 6.0, at 80 C for 30 min, as previously
described (Ba¨ck et al., 2013b). To block the unspeciﬁc
binding, the sections were incubated in 4% BSA and
0.1% Triton-X-100 followed by overnight incubation with
mouse anti-TH antibody (1:2000, MAB318, Millipore) or
rat anti-DAT antibody (1:2000, MAB369; Millipore). Fol-
lowing the incubation in the biotinylated secondary anti-
bodies (1:200, anti-mouse or anti-rat, Vector Labs,
Burlingame, CA, USA), the signal was enhanced usingthe avidin–biotin–enzyme complex (ABC-kit, Vector Labs)
and visualized with 30,30-diaminobenzidine.Optical density
In experiments 1 and 2, the images of the TH-stained
sections were acquired with a digital camera (Nikon
Corp., Tokyo, Japan) attached to the stereomicroscope
(Nikon). For experiment 3, the images of the stained
sections were acquired with a 3DHistech scanner
(3DHistech, Budapest, Hungary) service provided by the
Institute of Biotechnology (http://www.biocenter.helsinki.
ﬁ/bi/histoscanner/index.html). The optical density of the
TH+ ﬁbers in the striatum was determined from six
sections from each rat by using ImagePro software
(Media Cybernetics, Inc., Rockville, MD, USA). The
results are given as a percentage of the intact side,
which was deﬁned as 100% as described previously
(Penttinen et al., 2016).TH+ cell counts
The number of TH-reactive cells in SNpc was estimated
using StereoInvestigator software (MicroBrightﬁeld,
Williston, VT, USA) as previously described (Penttinen
et al., 2016). Cells in SNpc were count bilaterally from
six sections from each animal using unbiased counting
Fig. 3. The eﬀects of intranigral (left) CDNF 10 mg combined with subthalamic stimulation (STN HFS). (A) Study design of experiment 3 for testing
the eﬀects intermittent STN HFS combined with CDNF. Cylinder tests were done on consecutive days with no stimulation, low stimulation, and high
stimulation. (B) The evolution of right limb use asymmetry when all wall touches were counted in the cylinder test compared to baseline (no
stimulation) of week 1. (C) The evolution of right limb use asymmetry when only ﬁrst wall touches were counted in the cylinder test compared to
baseline (no stimulation) of week 1. (D) Subthalamic stimulation-induced dyskinesias over time. E) Example of TH striatal optical densities at 8
weeks. (F) Tyrosine-hydroxylase-stained striatal optical density of TH+ ﬁbers compared to contralateral side at 8 weeks. (G) TH+ cell counts in the
substantia nigra compared to contralateral side at 8 weeks. (H) DA HPLC results at 4 weeks. (I) DOPAC HPLC results at 4 weeks. Data expressed
as mean ± SEM, *p< 0.05, (*) <0.05 when weeks 2 and 3 were analyzed together.
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Fig. 4. (A) Study design of experiment 4 for testing the combination of intranigral (left) CDNF 10 mg and STN lesion (STNL). (B) Front limb
measured by all touches with the wall during rearing movements in the cylinder test at baseline before CDNF and STNL and at 1, 3, and 6 weeks
after. (C) Front limb measured by ﬁrst touches with the wall during rearing movements in the cylinder test use at baseline before CDNF and STNL
and at 1, 3, and 6 weeks after. (D) The number of apomorphine-induced rotations at 4 and 7 weeks after CDNF and STNL. (E) Optical density of TH
immunohistochemistry of lesioned side compared to the unlesioned side. (F) The number of TH+ cells in SNpc compared to the unlesioned side.
(G) HPLC results for percentage of dopamine (DA) on the lesioned side compared to the unlesioned side. (H) HPLC results for percentage of
DOPAC on the lesioned side compared to the unlesioned side. Data expressed as mean ± SEM, *p< 0.05, **p< 0.01.
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a percentage of the intact side.Stimulation speciﬁcations
In experiment 3, the rats received HFS to STN through
the implanted electrodes. The rats were able to move
freely during all stimulations. All stimulations were
conducted with a frequency of 130 Hz and pulse width
of 60 ms delivered with a STG 4004 external impulse
generator (Multichannel Systems, Reutlingen,
Germany). The stimulations took place on weeks 1, 3,
5, and 8 after the implantation. Each weekly time point
comprised three individual daily stimulation sessions.
On day 1, each rat was tested for stimulation-induced
dyskinesias by increasing the current stepwise from 25
mA to 400 mA or to the maximum currents tolerated by
the animal. The dyskinesia was scored on a 0–4 rating
scale. On the second day of stimulation, the rats were
tested in a cylinder for front paw rearing activity with
stimulation current just below any signiﬁcant front limb
dyskinesia (front limb dyskinesia rating 2, low
stimulation), and on the third day, this was performed
with the stimulation amplitude just below the level where
stimulation produced 10 s of lasting front limb
dyskinesias (front limb dyskinesia rating 3, high
stimulation). As described in our currently unpublished
study (Huotarinen et al., submitted). Stimulation during
cylinder testing lasted for 10 min. Before euthanasia, the
rats were stimulated with the higher stimulation
amplitude for 60 min. The stimulation was stopped only
immediately before euthanasia.Analysis of striatal dopamine and metabolites
The rat striatum samples were homogenized in 0.5 ml of
homogenization solution consisting of six parts 0.2 M
HClO4 and one part antioxidant solution (1.0 mM oxalic
acid, 0.1 M acetic acid, and 3.0 mM L-cysteine;
(Kankaanpa¨a¨ et al., 2002)) with a Rinco ultrasonic
homogenizer (Rinco Ultrasonic AG, Romanshorn,
Switzerland). The homogenates were centrifuged at
20,800g for 35 min at 4 C. The supernatant was removed
to 0.5-ml Vivaspin ﬁlter concentrators (10,000 MWCO
PES; Sartorius, Stonehouse, UK) and centrifuged at
8600g at 4 C for 35 min. Filtrates containing monoami-
nes were analyzed using high-pressure liquid chromatog-
raphy with electrochemical detection. Analyses of DA and
its main metabolites, 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), and 5-HT were per-
formed (Airavaara et al., 2006; Valros et al., 2015).Statistics
All statistical analyses were done by SPSS 24.0 (IBM,
Armonk, NY, USA). All variables were tested for
normality with Shapiro–Wilks and equality of variance
with Levene’s test, and parametric or nonparametric
tests were used accordingly. Comparisons between
multiple groups were done with ANOVA followed by
Tukey’s post hoc test for a comparison between all study
groups; Dunnett’s test was used to compare groups thatreceived treatments to the baseline group (vehicle only).
ANOVA tests were one-way ANOVA unless otherwise
stated. Nonparametric comparisons for multiple groups
were done with Kruskal–Wallis test or with Friedman’s
test for repeated variables, followed by post hoc
Bonferroni corrected Mann–Whitney test. Student’s t-test
was used when comparing two groups for parametric
variables and Mann-Whitney for nonparametric
variables. All statistical tests were two-sided. P-values
<0.05 were decided to be statistically signiﬁcant.RESULTS
Experiment 1, CDNF dose-dependent response given
at 4 weeks following the 6-OHDA lesion
First, we analyzed the eﬀects of various doses of intranigral
CDNF in the rat 6-OHDA MFB model of advanced PD.
There was no diﬀerence in apomorphine-induced
contralateral rotations before NTF injections at 2 and 4
weeks after 6-OHDA injection (2 weeks v2(6) = 4.909, p
=0.555 and 4 weeks v2(6) = 2.907, p=0.820p=0.725)
CDNF delivered as a single intranigral injection (1,
3.3, 10, 33, or 100 mg) 4 weeks post-lesion did not
produce any consistent eﬀect on the drug-induced
rotation behavior compared to the vehicle (PBS)
(Fig. 1B; 6–16 weeks v2(6) = 13.4–16.3, p= 0.012–0.0
38, all post hoc tests p> 0.6, across weeks 6–16 and
all CDNF concentrations). GDNF at 100 mg led to a
marked reduction of rotations compared to PBS (post
hoc vs. PBS 0.0235, 0.0078, 0.0069 and 0.0093) and to
rotations at 4 weeks at all time points after NTF injection
(Friedman’s v2(4) = 12.65, p= 0.13, post hoc weeks 8,
12 and 16 p= 0.050, 0.008 and 0.020 respectively).
However, when all apomorphine-induced rotations after
NTF injections were analyzed together, CDNF
concentrations 1 mg and 10 mg reduced the
apomorphine-induced rotations compared to PBS,
although not signiﬁcant for 10 mg (v2(6) = 54.69, p<
0.0001, post hoc 0.0307 and 0.10 respectively). When
the sum of apomorphine-induced rotations was
compared to weekly rotations at the week 4 baseline
before NTF injection, the sum of the rotations was
signiﬁcantly diﬀerent for CDNF 10 mg and GDNF 100 mg
compared to PBS (Fig. 1C; v2(6) = 63.23, p< 0.0001,
post hoc p= 0.0016 and p< 0.0001 respectively).
GDNF-treated animals lost body weight at 1 week after
injection (F[6,82] = 18.623, p<0.001, post hoc GDNF vs.
all other groups p<0.0001, all other post hoc tests p>
0.9) (Fig. 1D), but CDNF had no eﬀect on body weight.
CDNF concentrations of 10, 33, or 100 mg or GDNF at
100 mg did not have an eﬀect on the optical density of TH
+ ﬁbers in the striatum (Fig. 1E, v2(4) = 4.53, p= 0.34).
Diﬀerent CDNF concentrations did not have an eﬀect on
the number of TH+ cells in the SNpc (Fig. 1F, F[3,44]
= 0.056, p= 0.982).Experiment 2, CDNF 10 mg given at 1 week after MFB
6-OHDA
Because there was some eﬀect of 10 mg CDNF when
given 4 weeks after the 6-OHDA lesion, we wanted to
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OHDA would improve the behavioral recovery (Fig. 2A).
The animals were balanced into diﬀerent treatment
groups based on amphetamine-induced rotations before
NTF injections between the treatment groups (v2(2) =
0.01, p= 0.99, data not shown). Neither CDNF 10 mg
nor GDNF 10 mg produced a decrease in apomorphine-
induced contralateral rotations at 3, 7, or 9 weeks
(Fig. 2B; p> 0.50 at all time points). The optical density
of TH-stained striata was similar in all groups (Fig. 2C;
v2(2) = 0.29, p= 0.86). There was no statistically
signiﬁcant diﬀerence in the number of TH+ cells in
SNpc (Fig. 2D; v2(2) = 2.48, p= 0.29). The number of
TH+ cells in the substantia nigra was 3.5% (SD 5.6),
5.4% (SD 5.6), and 10.9% (SD 15.54) compared to the
contralateral side. This was not statistically signiﬁcant
(Fig. 2D; v2(3) = 2.48, p= 0.29).
Experiment 3, the combination of CDNF and STN HFS
in the MFB 6-OHDA PD model
STN DBS is a standard treatment of advanced PD, and
we wanted to study the eﬀects of combined short-term
STN stimulation and intranigral CDNF in an animal
model of advanced PD to see whether the eﬀect of STN
stimulation would improve in CDNF-treated animals over
time (Fig. 3A).
Rats were balanced into groups based on
amphetamine-induced ipsilateral rotations prior to CDNF
injection and STN electrode implantations 1 week after
6-OHDA injection (v2(3) = 1.90, p= 0.59).
Stimulation amplitudes used through the experiment
were based on stimulation-induced dyskinesias: PBS +
STN HFS group: low stimulation 106.3 mA and high
stimulation 181.3 mA. For the CDNF + STN HFS group:
low stimulation 146.2 mA and high stimulation 250 mA.
There was a statistically signiﬁcant diﬀerence between
the chosen amplitudes for both low stimulation (U=
130.5, p= 0.030) and high Low- and high-stimulation
amplitudes corrected the front limb use asymmetry in
the cylinder test with both CDNF- and PBS-treated
animals at all time points signiﬁcantly (p< 0.001),
except for the PBS group at week 1 (v2(2) = 5.56, p=
0.062) and week 5 (v2(2) = 5.73, p= 0.057).
There were no statistically signiﬁcant diﬀerences in
front limb use asymmetry between the CDNF and
vehicle groups at any point (Fig. 3B and 3C; all p-values
>0.1 at all time points between respective stimulations
[BL, low stimulation and high stimulation]). However,
contralateral front limb use increased more at 2 and 3
weeks for CDNF-treated animals compared to PBS-
treated animals with both low- and high-stimulation
amplitudes when compared to week 1 baselines (no
stimulation); although, this was not statistically
signiﬁcant (Fig. 3C; p= 0.095 and p= 0.21; week 3, p
= 0.11 and p= 0.31, respectively, for low and high
stimulation). When ﬁrst touches with the wall at 2- and
3-week time points were analyzed together, the
diﬀerence was signiﬁcant for no stimulation and low
stimulation, but not for high-stimulation amplitudes
(baseline 11.94 SD 22.82 vs. 6.98 SD 19.13, U=
2.18, p= 0.029; low stimulation 6.01 SD 25.25 vs.15.05 SD 23.74, U= 2.29, p= 0.022 and high
stimulation 20.24 SD 27.17 vs. 40.53 SD 29.45, U=
1.93, p= 0.053). There were no statistically signiﬁcant
diﬀerences in the absolute values of STN HFS-induced
dyskinesias at any time point (Fig. 3D, p= 0.304–0.908).
In rats treated with the combination of CDNF and STN
HFS, the optical density of TH-stained striatum was
higher compared to contralateral side than in PBS and
STN–HFS treated animals (Fig. 3E and F, t-test p=
0.0347). However, the diﬀerence in striatal optical
density was not signiﬁcant for DAT staining (mean
11.12 SD 3.47 in PBS vs. 15.93 SD 6.92 in CDNF co-
treated rats, U= 0.85, p= 0.48). There was no
statistically signiﬁcant diﬀerence in the number of TH+
cells in the stimulated animals that received CDNF
compared to those that received PBS (Fig. 3G; 3.37%
vs. 4.79% of contralateral side, p= 0.3335). The
average DA levels in the lesioned side were 0.40–
2.34% (Fig. 3H) of the levels on the contralateral
unlesioned and untreated side, and there was no
diﬀerence between the study groups (v2(3) = 6.33, p=
0.086). The average DOPAC levels were 1.11–4.25% of
the contralateral side, and there was no diﬀerence
between the study groups (Fig. 3I; v2(3) = 2.06, p=
0.59). Two animals were excluded from the HPLC
analysis as outliers. HVA levels were measurable only
in two striata on the lesioned side. There was no
diﬀerence between study groups for 5-HT
concentrations and DOPAC/DA ratios. We also tested
the eﬀects of CDNF without electrode compared to PBS
without electrode, and there were no statistically
signiﬁcant diﬀerences in HPLC or behavioral tests at 4
weeks after injections.
Experiment 4, the combination of CDNF and STN
lesion in the MFB 6-OHDA PD model
Because there was a modest trend for additive or
synergistic eﬀect of short-term STN HFS and
intranigrally administered CDNF, we wanted to test if
STN lesion, mimicking chronic STN DBS and shown to
be neuroprotective when administered early after the 6-
OHDA lesion, would have a stronger synergistic eﬀect
with CDNF (Fig. 4A).
There was no diﬀerence in amphetamine-induced
rotations before the CDNF injections and STN lesioning
between the treatment groups (F[3,52] = 0.007, p=
0.999). In the histological analysis, 10 animals were
found to have macroscopic (1 mm or over) lesions in
the subthalamic area or thalamus, and they were
excluded from further analysis.
The combination of STN lesion and intranigral CDNF
reduced the apomorphine-induced rotations at 4 weeks,
whereas STN lesion or CDNF alone did not have an
eﬀect (Fig. 4D). Only animals with a combination of
CDNF and STN lesions rotated less at 4 weeks (F[3,41]
= 3.853, p= 0.16, post hoc Tukey for CDNF + STNL
vs PBS + PBS p= 0.014). At 7 weeks, there was no
signiﬁcant diﬀerences between the groups (v2(3) = 6.2,
p= 0.10).
The cylinder test results were analyzed separately for
all front limb touches and ﬁrst front limb touches made
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test before CDNF or STNL, there was no diﬀerences
between the groups for all touches (v2(3) = 3.49, p=
0.32) or ﬁrst touches (v2(3) = 1.31, p= 0.73).
CDNF alone had no eﬀect on contralateral front limb
use (Fig. 4B, C). At 1 week after CDNF and STNL when
all touches with the cylinder wall were analyzed
(animals with less than 20 touches on the wall were
excluded), only the STNL + CDNF group was diﬀerent
from the PBS + PBS group (v2(3) = 10.16, p= 0.017,
post hoc p= 0.047). At 3 weeks, all touches with the
cylinder wall were analyzed (animals with less than 20
touches were excluded), and only the rats that received
both the CDNF and STN lesion used the contralateral
front limb signiﬁcantly more compared to the PBS +
PBS group (v2(3) = 15.84, p= 0.001, post hoc p=
0.011). At 6 weeks, when all touches with the wall were
counted (animals with less than 10 touches were
excluded), there was a trend that showed the CDNF +
STNL animals used contralateral front limbs more
compared to the CDNF + PBS group (v2(3) = 6.52, p
= 0. 089).
When only ﬁrst touches with the wall were analyzed at
one week after NTF injections (animals with under 7
rearings excluded), the rats with the combination of
STNL and CDNF used the contralateral front limb more
compared to CDNF + PBS group (v2(3) = 11.02, p=
0.012, post hoc p= 0.012). At week 3, the rats that
received the combination of CDNF and STNL used the
contralateral front limb more than those receiving only
CDNF and PBS to STN (animals with under 7 rearings
excluded, v2(3) = 9.28, p= 0.026, post hoc p= 0.032).
Furthermore, CDNF + STNL animals used the
contralateral front limb more than the PBS + PBS
group; however, this was not statistically signiﬁcant
(post hoc p= 0.227). At 6 weeks, the number of
rearings was so low that no meaningful statistical
analysis for ﬁrst touches was possible.
When the evolution of front limb use was compared to
the baseline before CDNF injection or STNL, only the
treatment group with the combination of CDNF 10 mg
and STNL improved their contralateral front limb use
(Fig. 4B, C). This eﬀect was seen with all touches at 3
(Friedman’s v2 = 9.171, p= 0.027, post hoc p<
0.001), all other p-values >0.2) and for ﬁrst touches at
1 and 3 weeks (Friedman’s v2 = 13.91, p= 0.001, post
hoc p= 0.093 and 0.002 respectively, all other p-values
>0.40, week 6 excluded from analysis due to the low
number of rearings).
The optical density of TH-stained striatum showed no
statistically signiﬁcant diﬀerences between the groups
(Fig. 4E; v2(3) = 4.347, p= 0.226). There was no
diﬀerence in the number of TH+ cells in SNpc (Fig. 4F;
v2(3) = 0.51, p= 0.92). HPLC analysis from the
striatum samples showed no statistically signiﬁcant
diﬀerences between the groups for dopamine content
(Fig. 4G; v2(3) = 2.04, p= 0.57) or DOPAC content
diﬀerences between groups (Fig. 4H; v2(3) = 2.97, p=
0.40). There was no diﬀerence between the study
groups for 5-HT concentrations and DOPAC/DA ratios.We also performed the previous statistical tests with
the excluded rats that had a macroscopic lesion from
IBOT, and this had no major inﬂuences on the results or
their signiﬁcance, apart from the fact that the decrease
in apomorphine-induced rotations at 4 weeks for the
CDNF + STNL group compared to PBS + PBS group
was not signiﬁcant in the other post hoc test (F[3,50] =
2.211, p= 0.087, post hoc Tukey p= 0.085, Dunnett’s
p= 0.049).DISCUSSION
We studied the eﬀects of CDNF alone or in combination
with STN DBS on restoring motor function and
nigrostriatal pathway phenotype in a rat MFB 6-OHDA
lesion model of advanced PD. Positive synergistic
behavioral eﬀect was found without robust histochemical
or neurochemical recovery. Those are in line with
previous reports indicating that CDNF produces partial
reversal of the behavioral 6-OHDA hemiparkinsonian
defects without changes in TH or monoamine
transmitter levels (Ba¨ck et al., 2013a), and that the corre-
lation between degree of striatal TH loss and
apomorphine-induced rotations is low (Kirik et al., 1998).
CDNF alone when given after complete lesion of the
nigrostriatal dopamine pathway did not have an eﬀect in
this late-stage PD model, even at higher concentrations.
These results further indicate that only in partial
axonopathy of SNpc dopamine neurons CDNF can
restore dopamine neuron circuitry as earlier suggested
(Lindholm et al., 2007; Voutilainen et al., 2011). Indeed,
it has been indicated that in order for NTF-induced neu-
rorestoration to occur there needs to be viable dopamine
neurons in the SNpc (Domanskyi et al., 2015). The small
putative behavioral eﬀects did not correlate with cell num-
bers and ﬁber densities, as has been described previously
(Ba¨ck et al., 2013a). As shown in other studies, intranigral
GDNF delivery of 100 mg produced a decrease in
apomorphine-induced rotational behavior (Hoﬀer et al.,
1994) without an increase in striatal TH-levels
(Bowenkamp et al., 1995). However, unlike GDNF, none
of the doses of CDNF produced a reduction in body
weight at 1 week after NTF injection. This eﬀect of GDNF
on body weight has been described before for intranigral
injections in rats (Hoﬀer et al., 1994; Martin et al., 1996;
Lapchak et al., 1997) and monkeys (Gash et al., 1995).
This implies that CDNF has a more favorable overall
eﬀect on general well-being and functioning. This overall
negative ﬁnding of the eﬃcacy of CDNF alone in the rat
model of advanced PD strengthens the importance of
the ﬁndings when CDNF was combined with STN HFS
and STNL.
For rodent models of PD and if neuroprotection or
neurorestoration by various compounds are being
studied, it is customary to make moderate striatal
lesions by injecting small doses of 6-OHDA into the
striatum itself (Penttinen et al., 2016). The idea is that
there is enough intact dopaminergic innervation left in
the striatum to allow meaningful possibilities to modify it.
With this technique, several NTFs have shown both neu-
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models of PD (Airavaara et al., 2012a,b). 6-OHDA injec-
tions into the MFB used in the current study caused seri-
ous dopaminergic damage that reduced striatal dopamine
levels close to zero. It is practically impossible to restore
this damage by any NTF treatment, even less so if the
proteins are administered close to the SN, not to the stria-
tum. It is quite surprising that a nigral dose (100 mg admin-
istered 4 weeks post-lesion) of GDNF was able to
signiﬁcantly reduce the apomorphine-induced turnings
without any biochemical or histochemical recovery. The
mechanism of this behavioral response remains obscure
although previous studies indicate that the eﬀect is medi-
ated by increased dopamine neurite growth in the sub-
stantia nigra pars reticulata (Bowenkamp et al., 1995).
Instead, similar CDNF treatments, up to 100 mg, were
much weaker, and there was no dose–response. A similar
lack of eﬃcacy of both GDNF and CDNF at 10 mg was evi-
dent, even if NTFs were given 1 week post-lesion.
Considering these mainly negative ﬁndings, it was
quite rewarding to see in an equally serious nigrostriatal
dopamine pathway damage model that even 10 mg of
nigral CDNF was able to add the eﬃcacy of STN HFS
in the cylinder test at several time points post-lesion.
The beneﬁcial eﬀects were accompanied by increased
optical densities of TH in the striatum but not with any
change in the striatal dopamine (or metabolite) levels or
TH+ cells in the SNpc.
A similar ﬁnding, supporting the additive eﬀects of
CDNF and STN HFS, was seen when nigral CDNF
injections were combined to STN lesion. The STN lesion
is mimicking the action of prolonged STN HFS. Now, a
functional recovery was seen in two behavioral tests:
apomorphine-induced turning and cylinder test. No
notable recoveries were seen in striatal dopamine (and
metabolite) or TH immunoreactivity in the SNpc or TH
optical density in the striatum.
Overall, there seems to be a putative synergistic or
additive eﬀect of intranigral CDNF and stimulation or
lesioning of the STN that was seen mainly in the
behavioral tests. Whether this eﬀect is unique to CDNF
is a matter for future studies. The mechanism of this
putative synergistic eﬀect requires further studies, but
there are previous reports on the eﬀects of CDNF
combined with either GDNF (Voutilainen et al., 2017) or
MANF (Cordero-Llana et al., 2015). Also, several NTFs
are required to protect SNpc neurons in culture from
MPP+ toxicity (Jaumotte et al., 2016). An interesting
possibility is that some of the synergies can be explained
by the NTF-like eﬀects of STN DBS, which has been
shown to increase BDNF levels in the dopaminergic sys-
tem of 6-OHDA-lesioned rats (Spieles-Engemann et al.,
2011), and a recent study has reported that signaling
mediated by the BDNF receptor TrkB could mediate both
neuroprotective and short-term behavioral eﬀects
(Fischer et al., 2017). It is well-known that neuronal activ-
ity aﬀects the levels of many NTFs, including BDNF,
GDNF, CDNF, and MANF. Moreover, neuronal and elec-
trical activity is known to stimulate the synthesis of BDNF
(Kolarow et al., 2007) and GDNF (Lonka-Nevalaita et al.,
2010). Thus, the synergistic cross-talk of exogenouslyadded and DBS-induced endogenous NTFs may at least
partially explain the results obtained. It is also possible
that the interaction can be mediated by a dopamine-
independent mechanism, perhaps by aﬀecting other neu-
rotransmitter systems downstream of the nigrostriatal
pathway.
Unfortunately, the observed eﬀects seen were at least
partly relatively short term, and future studies should
asses the eﬀect of longer term CDNF treatments, for
example, with a minipump combined to DBS. We
modeled long-term STN DBS with a STN lesion, which
shares only some of the same mechanisms with STN
DBS (Bacci et al., 2004), and the results might be diﬀerent
with continuous long-term DBS. Although STN DBS has
largely replaced STN lesions, the clinical use of STN
lesion has been reported also quite recently with less
side-eﬀects (Jourdain et al., 2014) whereas earliest stud-
ies with various lesioning methods had serious problems
(Cooper, 1953) (Cooper, 1960). However, the use of
STN lesion as a model for chronic DBS limits the transla-
tional potential of our studies. Nevertheless, our data
encourage animal trials using long-term experimental
DBS combined to NTF treatments to further study the
translational potential of our results, although our data
seem to support the hypothesis that STN DBS works at
least partially by inactivating STN neural network. It is
interesting that the behavioral eﬀect of the combination
was seen without changes in TH or monoamine levels,
which indicates that the combination of NTF and STN
DBS may be beneﬁcial in advanced PD, where the possi-
bilities of neurorestoration are generally quite modest
(Olanow et al., 2015). This could also provide a rationale
for clinical trials where NTFs could be combined with STN
DBS. The NTF injection site (SNpc) used in this study can
be reached through a similar trajectory as the one used
for STN DBS clinically. Additionally, it has been recently
suggested that DBS therapy could be combined with viral
vector mediated gene therapy or stem cell implantations
(Rowland et al., 2016).
We used two behavioral tests to study the behavioral
eﬀects of the combination of STN lesion and CDNF, the
cylinder test and apomorphine-induced rotation.
Additionally, amphetamine-induced rotations were used
as a baseline measure to balance the experimental
groups. Apomorphine-induced rotations develop more
slowly and require the development of supersensitivity
of the post-synaptic striatal neurons and thus provide
indirect measurement of dopamine depletion sensitive
for severe dopamine depletion relevant for the model of
advanced PD used in this study (Hudson et al., 1993).
Only one behavioral test was used to study the combina-
tion of STN HFS and the eﬀect was weak and short-term.
The fact that we found no robust histo- or biochemical
changes stresses that these putative behavioral eﬀects
should be conﬁrmed by other behavioral tests such as
the forelimb adjusting step test and the staircase test,
which could also provide for added sensitivity.
The ineﬀectiveness of NTFs alone in the used model
of advanced PD (6-OHDA MFB lesion) indicates that
NTF-treatments should be started clinically earlier in the
disease. The treatment of patients with a less severe
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striatum is already lacking TH+ ﬁbers 5 years after
diagnosis (Kordower et al., 2013). Moreover, the results
of clinical NRTN gene therapy trials indicate a positive
eﬀect in patients treated less than 5 years after diagnosis
(Bartus and Johnson, 2017a). However, the accuracy of
the initial diagnosis of PD is low (Joutsa et al., 2014),
and a follow-up period of 5 years has been suggested to
exclude patients with atypical PD before STN DBS
(Bronstein et al., 2011); however, suggestions for earlier
time points have been made (Eijkholt et al., 2017). The
synergistic combination of NTFs and DBS could oﬀer an
opportunity to provide both eﬀective symptom control
and neurorestorative treatment while complying with the
requirement of diagnostic follow-up.
Our study showed that there is an additive or
synergistic eﬀect of STN DBS and CDNF in an animal
model of advanced PD where NTFs have not had good
neurorestorative eﬀect. This favorable interaction may
be important in planning future clinical NTF trials in
advanced PD patients. The better eﬀect of the NTF and
DBS combination when compared to either treatment
alone provides a rationale for studying other
combinations of neurorestorative and symptomatic
treatments.
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